|
|
|
25.06.26 - 20:24
|
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy (24/7 Wall St.)
|
|
|
Abbott Laboratories (NYSE:ABT) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise compounds and its medical devices unit posts double-digit growth. Abbott spans medical devices, diagnostics, established pharmaceuticals, and nutrition, with Robert B. Ford as CEO. FreeStyle Libre, the ... Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy...
|
|
|
24.06.26 - 19:42
|
Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy (24/7 Wall St.)
|
|
|
Abbott Laboratories (NYSE:ABT) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused portfolio something rare: cash compounding that does not require monitoring. Pillar One: Durability Built Into the Business Model Abbott's revenue flows from four distinct segments ... Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.06.26 - 20:33
|
Abbott declares 410th consecutive quarterly dividend (PR Newswire)
|
|
|
ABBOTT PARK, Ill., June 12, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 410th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 17, 2026,......
|
|
|
|
|
|
|
|
|
|
|
|
|
30.05.26 - 00:24
|
KBRA Assigns AA+ Rating to State of Illinois, Build Illinois Bonds (Sales Tax Revenue), Junior Obligation Series A and B of June 2026; Affirms Parity Debt; Stable Outlook (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--#creditratingagency--KBRA assigns a long-term rating of AA+ with a Stable Outlook to the State of Illinois (the "State"), Build Illinois Bonds (Sales Tax Revenue Bonds), Junior Obligation Series A and B of June 2026 (the "Junior Bonds"). KBRA additionally affirms the long-term rating of AA+ with a Stable Outlook for the State's outstanding parity Junior Obligation Build Illinois Bonds.
Key Credit Considerations
The rating actions were because of the following key credit considerations:
Credit Positives
Security provisions are strong and include a priority lien on State sales tax revenues (after debt service payments on the Senior Obligation Build Illinois Bonds), a continuing appropriation requirement, and strong non-impairment language.
Junior Bonds' additional bonds test (ABT) requires 10.2x coverage of MADS on combined debt outstanding, limiting the potential to overleverage.
The statewide sales tax base is expansive and diverse, highlighted by combined lien debt service co...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
